From Globe Newswire Bionano Genomics, Inc. (NASDAQ: BNGO), a life sciences instrumentation company that develops and markets the Saphyr® system, a genome imaging platform for ultra-sensitive and ultra-specific genome-wide structural variation detection, today announced that leading organizations, including PerkinElmer Genomics and the University of Iowa, have adopted Saphyr for use in their clinical genomics laboratories. … Read More »
New genetic test being developed for FSHD
FSHD Gene May Help Tumors Evade the Immune System
BY ALEXANDRA BELAYEW, MONS, BELGIUM DUX4, the gene that plays a key role in facioscapulohumeral muscular dystrophy (FSHD), is gaining unexpected notoriety in cancer research. According to a recent study1 from the Fred Hutchinson Cancer Research Center in Seattle, Washington, gene mutations in tumor cells can cause a re-expression of DUX4 in malignant tissues. What’s… Read More »
Fulcrum Announced Results of Phase 1 Clinical Trial of Losmapimod
Data presented in an oral presentation at World Muscle Society meeting highlighted safety, tolerability, pharmacokinetics and target engagement of losmapimod in patients with facioscapulohumeral dystrophy. CAMBRIDGE, Mass., Oct. 04, 2019 (GLOBE NEWSWIRE) — Fulcrum Therapeutics, Inc. (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, today announced preliminary… Read More »
FSHD Society Announces 2020 Conferences
The nation’s capital will host the world’s premier conferences on facioscapulohumeral muscular dystrophy for all stakeholders The FSHD Society’s 27th annual International Research Congress (IRC) will be held on June 25-26, 2020, at the Washington Hilton in Washington, DC. It will be followed on June 27-28 by FSHD Connect, the Society’s biennial global conference bringing… Read More »
Dyne Therapeutics to support ReSolve study of FSHD
From BusinessWire Dyne Therapeutics, a biotechnology company pioneering targeted therapies for patients with serious muscle diseases, today announced its support for the ReSolve study, an ongoing natural history study designed to inform the development of therapies for facioscapulohumeral muscular dystrophy (FSHD). ReSolve (Clinical Trial Readiness to Solve Barriers to Drug Development in FSHD) is an observational study run… Read More »